Reviewed by MedNext Clinical Team
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation, but they carry a class-wide risk of cardiovascular, gastrointestinal, and renal adverse effects. Among the commonly available NSAIDs, naproxen has accumulated the most favourable cardiovascular safety evidence [1].
Cardiovascular Safety Compared to Other NSAIDs
A landmark network meta-analysis comparing the cardiovascular effects of multiple NSAIDs found that naproxen had the most favourable cardiovascular risk profile, while diclofenac, ibuprofen (at high doses), and selective COX-2 inhibitors such as etoricoxib and celecoxib showed elevated risks of myocardial infarction and stroke [1]. The mechanism likely relates to naproxen's balanced inhibition of both COX-1 and COX-2, which more closely resembles the effect of aspirin on thromboxane/prostacyclin balance than the COX-2-selective agents.
Implications for Prescribing in Cardiovascular Disease
In patients with established cardiovascular disease or multiple cardiovascular risk factors who require an NSAID, naproxen is generally preferred over diclofenac or COX-2 inhibitors when an NSAID cannot be avoided. It should still be used at the lowest effective dose for the shortest necessary duration, and co-prescription of a proton pump inhibitor (PPI) is strongly advisable.
Gastrointestinal Risks
Like all NSAIDs, naproxen inhibits COX-1-mediated prostaglandin synthesis in the gastric mucosa, reducing the protective mucus and bicarbonate layer. This predisposes to peptic ulceration, upper GI bleeding, and perforation. The GI risk with naproxen is not lower than with other traditional NSAIDs — indeed, some data suggest it may be higher than with ibuprofen at standard doses. Concurrent PPI use (e.g., omeprazole 20 mg once daily) significantly mitigates this risk and should be prescribed routinely in patients over 65, those with prior peptic ulcer disease, or those on anticoagulants or corticosteroids.
Renal Monitoring
NSAIDs reduce renal prostaglandin synthesis, which can precipitate acute kidney injury in patients who are volume-depleted, have pre-existing chronic kidney disease, or are on ACE inhibitors or ARBs. Renal function should be checked before initiating in at-risk patients, and patients should be advised to temporarily stop naproxen during episodes of dehydration or intercurrent illness (sick day rules).
Practical Summary
- Prefer naproxen over diclofenac or COX-2 inhibitors when cardiovascular risk is a concern
- Co-prescribe a PPI for gastric protection in higher-risk patients
- Avoid or use with caution in renal impairment, and check renal function in at-risk groups
- Use the lowest effective dose for the shortest necessary duration
- Avoid in the third trimester of pregnancy
References
- Trelle S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.